SRDX - Surmodics, Inc.
| Previous Close | 60.25 |
| Open | 60.40 |
| Bid | 58.95 x 100 |
| Ask | 65.00 x 500 |
| Day's Range | 60.15 - 61.78 |
| 52 Week Range | 24.25 - 61.78 |
| Volume | 151,005 |
| Avg. Volume | 87,858 |
| Market Cap | 805.423M |
| Beta | 0.38 |
| PE Ratio (TTM) | 30,375.00 |
| EPS (TTM) | 0.00 |
| Earnings Date | Nov 14, 2017 - Nov 20, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.50 |
- Zacks•23 days ago
5 Top Performing Stocks of the Best ETF of 1H2018
Inside the top performing stocks of the top ETF of the first half of 2018.
- Zacks•last month
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
- InvestorPlace•last month
4 of the Best Efficient Stocks to Buy for Superb Returns
Inventory level is one of the key indicators of a company’s business health. While a high inventory level may indicate that the company is going through a rough patch in terms of sales, a dwindling level may indicate that it will run out of stock in a favorable sales condition. This is where inventory turnover comes into play.
- Zacks•last month
4 of the Best Efficient Stocks to Buy for Superb Returns
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
- Zacks•last month
Here's Why You Must Add Surmodics (SRDX) to Your Portfolio
Surmodics' (SRDX) efforts to improve research and development stature bode well.
- Zacks•last month
SYK or SRDX: Which is a Better Medical Product Stock?
Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.
- Zacks•2 months ago
4 Medical Device Stocks with Solid Potential to Buy Now
The Medical Device tax suspension spells good times for MedTech bigwigs.
- Zacks•2 months ago
Surmodics (SRDX) Hits Fresh Highs: Is There Still Room to Run?
Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.
- Zacks•2 months ago
Surmodics (SRDX) Gains From Consistent Efforts to Boost R&D
Surmodics' (SRDX) consistent focus on research and development activities has been driving growth. The company is expected to make continued progress throughout the remainder of fiscal 2018.
- Business Wire•2 months ago
Surmodics to Present at Jefferies 2018 Global Healthcare Conference
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, interim vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies 2018 Global Healthcare Conference in New York City on Friday, June 8, 2018, at 11:30 a.m. ET (10:30 a.m. CT).
- Zacks•2 months ago
Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM
Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM
- American City Business Journals•2 months ago
Twin Cities' biggest companies are raking it in. Here's what's driving the profit boom.
Corporate America's bottom line is booming on the back of a resurgent economy and the prospect that the good times are just getting started.
- Zacks•2 months ago
5 Top Efficient Stocks to Keep on Your Radar
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
- GlobeNewswire•2 months ago
Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer
EAGAN, Minn., May 16, 2018-- Biothera Pharmaceuticals, Inc., announced the appointment of Andrew D.C. LaFrence, CPA as Senior Vice President and Chief Financial Officer, effective May 29. Biothera Pharmaceuticals ...
- Business Wire•2 months ago
Surmodics Announces Leadership Change and Appointment of Interim CFO
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018. Following LaFrence’s departure, Timothy J. Arens, Vice President of Corporate Development and Strategy, will serve as interim CFO. “We greatly appreciate the contributions Andy has made during his tenure at Surmodics and wish him the best in his future endeavors,” said Gary Maharaj, President and Chief Executive Officer of Surmodics.
- Zacks•2 months ago
Surmodics (SRDX) Hits a 52-Week High, Can the Run Continue?
Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.
- Business Wire•2 months ago
Surmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today it has reached an agreement with Embolitech to acquire an innovative thrombectomy platform technology and related intellectual property with broad potential peripheral vascular applications. Under the agreement, Surmodics will pay $5 million up front, and additional amounts related to various regulatory milestones. The addition of this technology to the Surmodics peripheral vascular pipeline strengthens the company’s focus on developing highly differentiated whole-product solutions for its medical device customers.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of SRDX earnings conference call or presentation 2-May-18 12:30pm GMT
Q2 2018 Surmodics Inc Earnings Call
- Zacks•2 months ago
Surmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises View
Surmodics' (SRDX) second-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
- Business Wire•3 months ago
CORRECTING and REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance
The fifth bullet in the Recent Highlights section should read: EPS of $0.11, Non-GAAP EPS of $0.07 . The correct figure of $0.07 is represented in the Second Quarter Fiscal 2018 Financial Results section and throughout the financial tables.
- Associated Press•3 months ago
SurModics: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Eden Prairie, Minnesota-based company said it had profit of 11 cents. Earnings, adjusted for non-recurring gains, came to 7 cents per share. The drug delivery technology company ...
- GlobeNewswire•3 months ago
Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital — What Drives Growth in Today's Competitive Landscape
NEW YORK, May 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vitamin ...
- Business Wire•3 months ago
Surmodics Announces FDA Clearance of a New .018” Low-Profile PTA Balloon Dilation Catheter
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration 510 clearance for its .018” Low-Profile percutaneous transluminal angioplasty balloon dilation catheter, designed and indicated for a broad range of peripheral vascular applications.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of SRDX presentation 27-Mar-18 6:30pm GMT
Surmodics Inc at Needham Healthcare Conference
